CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones


CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today provided corporate updates and key objectives for 2025.

Continue reading here:
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

Related Posts